ReShape Lifesciences (RSLS) Stock Price, News & Analysis

Company Overview

ReShape Lifesciences, Inc. (NASDAQ: RSLS) is a medical device company dedicated to developing and commercializing minimally invasive solutions for obesity and metabolic health. The company’s flagship product, the ReShape Dual Balloon System, is an endoscopically delivered intragastric device designed to promote weight loss through gastric volume displacement. By offering a non-surgical alternative to traditional bariatric procedures, ReShape aims to address a growing global demand for less-invasive interventions in the management of obesity and related comorbidities.

Founded in 2010 and headquartered in San Clemente, California, ReShape Lifesciences has expanded its presence through regulatory approvals and strategic partnerships. The ReShape Dual Balloon System has received clearance from the U.S. Food and Drug Administration, as well as CE Mark certification in Europe. These clearances have enabled the company to establish a commercial footprint in key markets across North America and Europe, and to position its products for broader adoption by physicians and integrated healthcare networks.

In addition to its core intragastric balloon technology, the company invests in ongoing research and development to enhance device performance and patient outcomes. This commitment extends to clinical studies focused on optimizing treatment protocols and exploring adjunctive therapies. ReShape’s product pipeline reflects a strategy of innovation in endoscopic and minimally invasive solutions, with the goal of delivering safe, effective, and scalable options for patients battling obesity.

Under the leadership of its CEO and President, Michael R. Marinaro, and supported by a management team with deep expertise in medical technology commercialization, ReShape Lifesciences continues to pursue growth opportunities and collaborative ventures. The company’s board of directors comprises industry veterans who guide strategic planning, regulatory affairs, and market expansion initiatives. Together, they aim to position ReShape as a trusted partner in the global fight against obesity, driving long-term value through clinical efficacy and patient-centric care.

Key Stats

• Today's Range: $2.36 to $2.50
• 50-Day Range: $2.29 to $11.13
• 52-Week Range: $2.23 to $347.86
• Volume: 125,709 shs
• Average Volume: 790,502 shs
• Market Capitalization: $5.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

ReShape Lifesciences Stock Analysis - MarketRank™

ReShape Lifesciences scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ReShape Lifesciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ReShape Lifesciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ReShape Lifesciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.42% of the float of ReShape Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

ReShape Lifesciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ReShape Lifesciences has recently decreased by 78.22%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ReShape Lifesciences does not currently pay a dividend.

Dividend Growth

ReShape Lifesciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.42% of the float of ReShape Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

ReShape Lifesciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ReShape Lifesciences has recently decreased by 78.22%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

ReShape Lifesciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ReShape Lifesciences this week, compared to 1 article on an average week.

Search Interest

2 people have searched for RSLS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ReShape Lifesciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of ReShape Lifesciences is held by insiders.

Percentage Held by Institutions

Only 22.06% of the stock of ReShape Lifesciences is held by institutions.

RSLS Stock Analysis - Frequently Asked Questions

How have RSLS shares performed this year?

ReShape Lifesciences' stock was trading at $111.50 at the beginning of 2025. Since then, RSLS stock has decreased by 97.9% and is now trading at $2.38.

How were ReShape Lifesciences' earnings last quarter?

ReShape Lifesciences Inc. (NASDAQ:RSLS) announced its quarterly earnings data on Tuesday, May, 20th. The medical device company reported $18.98 earnings per share for the quarter. The medical device company earned $1.11 million during the quarter. ReShape Lifesciences had a negative trailing twelve-month return on equity of 251.90% and a negative net margin of 48.26%.

When did ReShape Lifesciences' stock split?

ReShape Lifesciences's stock reverse split on Monday, September 23rd 2024.The 1-58 reverse split was announced on Thursday, September 19th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of ReShape Lifesciences?

Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ReShape Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ReShape Lifesciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Digital Turbine (APPS), Nano Dimension (NNDM), CrowdStrike (CRWD) and

Company Calendar

• Last Earnings: 5/20/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:RSLS
• CIK: 1371217
• Web: www.reshapelifesciences.com
• Phone: (949) 429-6680
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($193.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.13 million
• Net Margins: -48.26%
• Pretax Margin: -47.82%
• Return on Equity: -251.90%
• Return on Assets: -59.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.53
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $8.01 million
• Price / Sales: 0.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($8.66) per share
• Price / Book: -0.27

Miscellaneous

• Outstanding Shares: 2,390,000
• Free Float: 2,386,000
• Market Cap: $5.69 million
• Optionable: Not Optionable
• Beta: 1.16